During the last session, Vincerx Pharma Inc (NASDAQ:VINC)’s traded shares were 16.05 million, with the beta value of the company hitting 1.13. At the end of the trading day, the stock’s price was $0.26, reflecting an intraday loss of -19.14% or -$0.06. The 52-week high for the VINC share is $9.37, that puts it down -3503.85 from that peak though still a striking 30.77% gain since the share price plummeted to a 52-week low of $0.18. The company’s market capitalization is $7.75M, and the average intraday trading volume over the past 10 days was 38.13 million shares, and the average trade volume was 6.43 million shares over the past three months.
Vincerx Pharma Inc (VINC) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. VINC has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be 0.
Vincerx Pharma Inc (NASDAQ:VINC) trade information
Vincerx Pharma Inc (VINC) registered a -19.14% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -19.14% in intraday trading to $0.26, hitting a weekly high. The stock’s 5-day price performance is 32.86%, and it has moved by -7.72% in 30 days. Based on these gigs, the overall price performance for the year is -77.73%. The short interest in Vincerx Pharma Inc (NASDAQ:VINC) is 0.42 million shares and it means that shorts have 0.77 day(s) to cover.
The consensus price target of analysts on Wall Street is $2, which implies an increase of 87.0% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2 and $2 respectively. As a result, VINC is trading at a discount of -669.23% off the target high and -669.23% off the low.
Vincerx Pharma Inc (VINC) estimates and forecasts
Statistics show that Vincerx Pharma Inc has outperformed its competitors in share price, compared to the industry in which it operates. Vincerx Pharma Inc (VINC) shares have gone down -64.34% during the last six months, with a year-to-date growth rate more than the industry average at 60.85% against 16.70.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -283.70%. While earnings are projected to return 59.79% in 2025.
VINC Dividends
Vincerx Pharma Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Vincerx Pharma Inc (NASDAQ:VINC)’s Major holders
Vincerx Pharma Inc insiders own 15.68% of total outstanding shares while institutional holders control 24.40%, with the float percentage being 28.94%. PROSIGHT MANAGEMENT, LP is the largest shareholder of the company, while 32.0 institutions own stock in it. As of 2024-06-30, the company held over 2.49 million shares (or 11.6281% of all shares), a total value of $2.02 million in shares.
The next largest institutional holding, with 1.99 million shares, is of ARMISTICE CAPITAL, LLC’s that is approximately 9.2897% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.61 million.
Also, the Mutual Funds coming in first place with the largest holdings of Vincerx Pharma Inc (VINC) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . Data provided on Sep 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 341.07 shares. This amounts to just over 1.01 percent of the company’s overall shares, with a $89633.0 market value. The same data shows that the other fund manager holds slightly less at 280.42, or about 0.83% of the stock, which is worth about $73693.0.
